The spondyloarthritides (SpA) is a group of rheumatic diseases characterised by inflammation in peripheral joints, axial inflammation, enthesitis and extraarticular disease manifestations. SpA is subdivided into several different disease entities of which psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are the largest. During later years the therapeutic options have increased when treating both patients with PsA and axSpA where patients not responding to conventional treatment may be treated with various biologics. Although TNF inhibitors are often used as first line biological treatment, not all patients have a sufficient response and thus become eligible for other mode of actions.
Novartis invites you to a streamed lecture with Lars-Erik Kristensen, Professor Rheumatology at Parker Institute, Copenhagen who will give a lecture on new data on biological switch in patients with SpA.
Lecturer: Professor Lars-Erik Kristensen, Parker Institute, Copenhagen
Time: Wednesday December 2nd at 12:00-13:00 CET
Venue: Webstreaming from film studio in Malmö.
For participation and to get a link for the streamed lecture, register in the form below latest November 23rd, 2020. Participation in the meeting requires approval from the head of department. Participation in the meeting is free of costs.
Medical Advisor Rheumatology
Novartis Sverige AB